How Pharmaceutical Market Research Works in MENA: Methods and Data Sources
How Pharmaceutical Market Research Works in MENA: Methods and Data Sources examines how pharmaceutical, medtech, and payer teams should interpret market signals in GCC and multinational. Commercial and insight leaders use this lens to align registration sequencing, tender strategy, and evidence plans with what regulators and payers actually reward—not generic global templates. Start with the healthcare market research hub and GCC market access guide when scoping cross-border programmes.
BioNixus publishes this briefing for market access, medical affairs, and strategy teams who need disciplined field intelligence without overstating unpublished clinical statistics. Where product-specific claims appear in source materials, we reference sponsor or regulator disclosures only; we do not invent trial outcomes or epidemiology figures.
For a scoped workshop on how pharmaceutical market research works in mena, contact BioNixus to align methodology, timelines, and stakeholder maps.
Key insights summary
- Geographic focus: GCC and multinational — align sampling, payer interviews, and dossier modules to local formulary and tender mechanics.
- Evidence discipline: Separate regulatory facts from commercial forecasts; Gulf uptake depends on NUPCO, MOHAP, and private insurer rules more than global headline market size.
- Research design: Pair quantitative healthcare research with qualitative KOL and payer depth when access narratives must survive committee scrutiny.
- Registration: SFDA registration strategy and UAE MOHAP and DHA market access pathways often recycle FDA or EU modules when Arabic labeling and pharmacovigilance plans are ready.
- Advisory: pharmaceutical market access consulting helps translate insight into tender-ready value stories.
- Methodology: Document sampling frames, screen-out logic, and validation steps before fieldwork—especially for scarce specialists and mixed-mode quant/qual programmes.
Detailed analysis
How Pharmaceutical Market Research Works in MENA: Methods and Data Sources
How Pharmaceutical Market Research Works in MENA: Methods and Data Sources examines how pharmaceutical, medtech, and payer teams should interpret market signals in GCC and multinational. Commercial and insight leaders use this lens to align registration sequencing, tender strategy, and evidence plans with what regulators and payers actually reward—not generic global templates. Start with the healthcare market research hub and GCC market access guide when scoping cross-border programmes.
BioNixus publishes this briefing for market access, medical affairs, and strategy teams who need disciplined field intelligence without overstating unpublished clinical statistics. Where product-specific claims appear in source materials, we reference sponsor or regulator disclosures only; we do not invent trial outcomes or epidemiology figures.
For a scoped workshop on how pharmaceutical market research works in mena, contact BioNixus to align methodology, timelines, and stakeholder maps.
Key insights summary
- Geographic focus: GCC and multinational — align sampling, payer interviews, and dossier modules to local formulary and tender mechanics.
- Evidence discipline: Separate regulatory facts from commercial forecasts; Gulf uptake depends on NUPCO, MOHAP, and private insurer rules more than global headline market size.
- Research design: Pair quantitative healthcare research with qualitative KOL and payer depth when access narratives must survive committee scrutiny.
- Registration: SFDA registration strategy and UAE MOHAP and DHA market access pathways often recycle FDA or EU modules when Arabic labeling and pharmacovigilance plans are ready.
- Advisory: pharmaceutical market access consulting helps translate insight into tender-ready value stories.
- Methodology: Document sampling frames, screen-out logic, and validation steps before fieldwork—especially for scarce specialists and mixed-mode quant/qual programmes.
Detailed analysis
How Pharmaceutical Market Research Works in MENA: Methods and Data Sources
How Pharmaceutical Market Research Works in MENA: Methods and Data Sources examines how pharmaceutical, medtech, and payer teams should interpret market signals in GCC and multinational. Commercial and insight leaders use this lens to align registration sequencing, tender strategy, and evidence plans with what regulators and payers actually reward—not generic global templates. Start with the healthcare market research hub and GCC market access guide when scoping cross-border programmes.
BioNixus publishes this briefing for market access, medical affairs, and strategy teams who need disciplined field intelligence without overstating unpublished clinical statistics. Where product-specific claims appear in source materials, we reference sponsor or regulator disclosures only; we do not invent trial outcomes or epidemiology figures.
For a scoped workshop on how pharmaceutical market research works in mena, contact BioNixus to align methodology, timelines, and stakeholder maps.
Key insights summary
- Geographic focus: GCC and multinational — align sampling, payer interviews, and dossier modules to local formulary and tender mechanics.
- Evidence discipline: Separate regulatory facts from commercial forecasts; Gulf uptake depends on NUPCO, MOHAP, and private insurer rules more than global headline market size.
- Research design: Pair quantitative healthcare research with qualitative KOL and payer depth when access narratives must survive committee scrutiny.
- Registration: SFDA registration strategy and UAE MOHAP and DHA market access pathways often recycle FDA or EU modules when Arabic labeling and pharmacovigilance plans are ready.
- Advisory: pharmaceutical market access consulting helps translate insight into tender-ready value stories.
- Methodology: Document sampling frames, screen-out logic, and validation steps before fieldwork—especially for scarce specialists and mixed-mode quant/qual programmes.
Detailed analysis
How Pharmaceutical Market Research Works in MENA: Methods and Data Sources
Pharmaceutical market research in the Middle East and North Africa (MENA) follows broadly similar principles to research in Western markets — but the data infrastructure, regulatory context, physician recruitment dynamics, and cultural considerations are substantially different. For pharmaceutical companies commissioning research in MENA for the first time, or evaluating research suppliers for GCC and Egypt studies, understanding how the research actually works is essential for making well-informed commissioning decisions.
This guide covers the primary research methods used in MENA pharmaceutical market research, how data is collected in each GCC market, and how to evaluate the quality of research suppliers operating in the region.
The Four Core Pharmaceutical Market Research Methods in MENA
1. Quantitative Physician Surveys
The most frequently commissioned type of pharmaceutical market research. A structured questionnaire is designed around specific research objectives — brand awareness, prescribing intent, message recall, treatment pathway mapping, competitor positioning — and administered to a representative sample of physicians in the target specialty and geography.
How recruitment works in MENA
Physician recruitment in GCC markets requires verification against national physician registration databases. In Saudi Arabia, the Saudi Commission for Health Specialties (SCHS) is the primary registration body. In UAE, DHA (Dubai) and DOH (Abu Dhabi) maintain separate registers. In Kuwait, the Kuwait Medical Association. In Egypt, the Egyptian Medical Syndicate. Reputable research agencies maintain physician panels pre-verified against these databases, enabling rapid recruitment of qualified respondents.
Survey administration methods
CATI (Computer-Assisted Telephone Interview) is common for shorter surveys (15–25 minutes) and markets where physicians are accessible by phone. Online panel surveys are increasingly used across the GCC where smartphone penetration is high. Face-to-face structured interviews are used for longer questionnaires, complex topics, or markets where telephone/online accessibility is lower (parts of Egypt, for example). All three methods are available through BioNixus across all MENA markets.
Typical specifications
- Sample size: 50–400 physicians per country per wave
- Survey length: 15–45 minutes
- Turnaround: 3–7 weeks from study design confirmation
- Languages: Arabic (Gulf dialect or Egyptian dialect as appropriate) and English
- Compliance: ICH-GCP — informed consent, data protection, anonymisation
What quantitative physician surveys tell you
Brand awareness and recall levels, prescribing frequency and patient share, treatment decision drivers, competitive positioning, message comprehension and persuasiveness, unmet medical needs, and physician perceptions of disease and treatment options.
What they do not tell you
Actual sales volumes, real-world patient outcomes, patient-level adherence data, or procurement and pricing dynamics. Physician-reported prescribing behaviour is a self-reported proxy for actual prescribing — it can differ from dispensing records due to recall bias and social desirability effects.
2. Hospital Sales Data Collection
The second core method — and one of BioNixus's primary differentiating capabilities in MENA. Hospital sales data is collected directly from the source of pharmaceutical dispensing: hospital pharmacy information systems (PIS), hospital procurement records, and physician prescription data.
How it works
BioNixus recruits a panel of hospitals in each GCC country and Egypt — typically 20–30% of the total hospital universe. Each panel hospital submits monthly dispensing data from its pharmacy information system. This data is cleaned, validated, and projected to the full hospital universe using stratification weights based on hospital size, type (public/private, teaching/non-teaching), and specialty profile.
Primary data sources
- Pharmacy dispensing records — actual units dispensed from hospital pharmacy by molecule, SKU, and in some cases department
- Procurement data — purchase orders submitted to NUPCO (Saudi Arabia), CMS (Kuwait), HMC (Qatar), or direct distributors — reflecting sell-in volumes
- Physician prescribing diaries — monthly reports from standing physician panels recording indication-level and patient-level prescribing, layered onto pharmacy data to add indication and patient context
How this differs from IQVIA audit data
IQVIA's GCC pharmaceutical audit is based on panel projections from a sample of pharmacies and distributors, without patient-level or indication-level resolution. BioNixus collects primary-source data with hospital-level, department-level, indication-level, and patient-level granularity — providing deeper insight than standard audit products, particularly in markets where IQVIA's panel coverage is thin.
3. KOL Mapping and Medical Affairs Research
Key Opinion Leader (KOL) mapping is the research process of identifying, profiling, and ranking the physicians most influential in shaping clinical practice in a given therapeutic area and geography.
How KOL mapping works in MENA
BioNixus combines three data sources for MENA KOL identification:
Publication analysis — systematic review of scientific publications authored by MENA-based physicians in target therapeutic areas, using bibliometric databases (PubMed, Scopus, Web of Science). Publication count, citation index, journal impact factor, and co-authorship networks are analysed.
Congress and advisory board activity — BioNixus tracks GCC and MENA physician participation in international and regional congresses (ASCO, ASH, ESC, ADA, and regional equivalents) as speakers, moderators, poster presenters, and guideline committee members.
Prescribing reach and institutional affiliation — A KOL's clinical influence is proportional to the number of patients under their care and the seniority of their institutional role. BioNixus assesses each identified KOL's departmental seniority, patient throughput, and ability to influence peer prescribing.
Output: Tiered KOL list (Tier 1 national/international leaders, Tier 2 regional/institutional leaders, Tier 3 emerging voices), influence heat maps by institution and geography, and recommended engagement strategy by tier.
GCC implications for sponsors and insight teams
Saudi Arabia
Registration and public uptake require SFDA dossiers, Arabic labeling, and often NUPCO engagement. Saudi Arabia healthcare research programmes should stress-test whether global value dossiers include Gulf-relevant budget impact and comparators.
United Arab Emirates
Federal and emirate policies may diverge; private insurance prior authorization can outpace public lists. UAE healthcare research helps map stakeholder paths in Dubai and Abu Dhabi.
Cross-GCC harmonization
Harmonized evidence packages—stability, pharmacovigilance, and conservative epidemiology—support faster cycles when FDA or EC reference approvals exist. Oral medicines may emphasize adherence counselling; specialty therapies require site-of-care readiness assessments.
Insight cadence
Quarterly payer interviews and annual epidemiology refreshes outperform one-off launch studies when formularies shift mid-year. Align research waves with SFDA and MOHAP scientific advice windows so evidence packages stay committee-ready.
BioNixus advisory
BioNixus supports GCC and multinational programmes with payer-ready narratives: SFDA/MOHAP dossier gap analysis, NUPCO tender mapping, bilingual KOL trackers, and competitive simulations. We combine quantitative healthcare research with pharmaceutical market access consulting so insight teams receive decision-grade recommendations—not slide recycling.
Recommended workstreams: (1) evidence and access storyline aligned to local committees; (2) registration timeline with conservative uptake assumptions; (3) field intelligence cadence for named competitors; (4) executive readouts for Riyadh, Jeddah, Dubai, and Abu Dhabi stakeholders. contact BioNixus to scope a 90-day briefing.
